Cargando…

Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit for the symptomatic relief of severe hypoglycemia: two randomized crossover non-inferiority studies

INTRODUCTION: To prevent medical sequelae of severe hypoglycemic emergencies, prompt and reliable rescue intervention is critically important. A ready-to-use, liquid stable glucagon, administered subcutaneously by glucagon autoinjector (GAI), Gvoke HypoPen (glucagon injection; Xeris Pharmaceuticals)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Christiansen, Mark P, Cummins, Martin, Prestrelski, Steven, Close, Nicole C, Nguyen, Anh, Junaidi, Khaled
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Emerging Technologies, Pharmacology and Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499286/ https://www.ncbi.nlm.nih.gov/pubmed/34620618 http://dx.doi.org/10.1136/bmjdrc-2021-002137

Ejemplares similares

Human Factors Usability and Validation Studies of a Glucagon Autoinjector in a Simulated Severe Hypoglycemia Rescue Situation
por: Valentine, Virginia, et al.
Publicado: (2019)

A Comparative Study of Dasiglucagon Ready-to-Use Autoinjector and Glucagon Emergency Kit During Rescue from Simulated Severe Hypoglycemia
por: Bailey, Naila Celeste, et al.
Publicado: (2022)

MON-LB115 Ready-To-Use Glucagon for the Prevention of Exercise-Induced Hypoglycemia in a Clinical Research Setting
por: Aronson, Ronnie, et al.
Publicado: (2020)

Effect of Mini-Dose Ready-to-Use Liquid Glucagon on Preventing Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes
por: Aronson, Ronnie, et al.
Publicado: (2023)

Use of glucagon in severe hypoglycemia is scarce in most countries, and has not been expanded by new ready-to-use glucagons
por: Pontiroli, Antonio E., et al.
Publicado: (2022)

Development of a Measure to Assess Attitudes Towards Nasal versus Autoinjector Glucagon Delivery Devices for Treatment of Severe Hypoglycemia
por: Bajpai, Sanjay K, et al.
Publicado: (2022)

OR22-3 Closed-Loop Glucagon Pump: A Novel and Effective Strategy for Post-Bariatric Hypoglycemia
por: Mulla, Christopher, et al.
Publicado: (2019)

Effect of Repeated Glucagon Doses on Hepatic Glycogen in Type 1 Diabetes: Implications for a Bihormonal Closed-Loop System
por: Castle, Jessica R., et al.
Publicado: (2015)

MON-LB110 A Phase 2 Evaluation of a Ready-To-Use Liquid Stable Continuous Subcutaneous Glucagon Infusion for the Treatment of Hypoglycemia Associated Autonomic Failure
por: Pettus, Jeremy H, et al.
Publicado: (2020)

Dasiglucagon, a next‐generation ready‐to‐use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial
por: Battelino, Tadej, et al.
Publicado: (2021)

Therapeutic Use of Intranasal Glucagon: Resolution of Hypoglycemia
por: Pontiroli, Antonio E., et al.
Publicado: (2019)

Systematic Literature Review and Indirect Treatment Comparison of Three Ready-to-Use Glucagon Treatments for Severe Hypoglycemia
por: Giménez, Marga, et al.
Publicado: (2023)

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events
por: Lingvay, Ildiko, et al.
Publicado: (2020)

Glucagon receptor antagonist upregulates circulating GLP-1 level by promoting intestinal L-cell proliferation and GLP-1 production in type 2 diabetes
por: Lang, Shan, et al.
Publicado: (2020)

Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK
por: Weiss, Tracey, et al.
Publicado: (2022)

Preference for Subcutaneously Administered Low-Dose Glucagon Versus Orally Administered Glucose for Treatment of Mild Hypoglycemia: A Prospective Survey Study
por: Tetzschner, Rikke, et al.
Publicado: (2019)

Optimization of a Glucagon-Like Peptide 1 Receptor Antagonist Antibody for Treatment of Hyperinsulinism
por: Peterson, Sean M., et al.
Publicado: (2023)

SAT-272 A Phase 2 Comparison of a Stable Liquid Glucagon to Placebo for the Treatment of Congenital Hyperinsulinism
por: Thornton, Paul, et al.
Publicado: (2019)

Inhaled Formoterol Diminishes Insulin-Induced Hypoglycemia in Type 1 Diabetes
por: Belfort-DeAguiar, Renata D., et al.
Publicado: (2015)

Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach
por: Kedia, Nitil
Publicado: (2011)

Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study
por: Rickels, Michael R., et al.
Publicado: (2016)

Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia
por: Umapathysivam, Mahesh M., et al.
Publicado: (2014)

Metabolic Syndrome Abolishes Glucagon-Like Peptide 1 Receptor Agonist Stimulation of SERCA in Coronary Smooth Muscle
por: Dineen, Stacey L., et al.
Publicado: (2015)

Early Loss of the Glucagon Response to Hypoglycemia in Adolescents With Type 1 Diabetes
por: Siafarikas, Aris, et al.
Publicado: (2012)

A Potential Role for Endogenous Glucagon in Preventing Post-Bariatric Hypoglycemia
por: Lobato, Carolina B., et al.
Publicado: (2020)

Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study
por: Shima, Kosuke Robert, et al.
Publicado: (2018)

Glucagon Receptor Signaling and Glucagon Resistance
por: Janah, Lina, et al.
Publicado: (2019)

Faster Use and Fewer Failures with Needle-Free Nasal Glucagon Versus Injectable Glucagon in Severe Hypoglycemia Rescue: A Simulation Study
por: Yale, Jean-François, et al.
Publicado: (2017)

Intraperitoneal and subcutaneous glucagon delivery in anaesthetized pigs: effects on circulating glucagon and glucose levels
por: Åm, Marte Kierulf, et al.
Publicado: (2020)

Transient Receptor Potential Vanilloid 1 Activation Enhances Gut Glucagon-Like Peptide-1 Secretion and Improves Glucose Homeostasis
por: Wang, Peijian, et al.
Publicado: (2012)

A glucagon analog chemically stabilized for immediate treatment of life-threatening hypoglycemia()
por: Chabenne, Joseph, et al.
Publicado: (2014)

Mitochondrial GTP Insensitivity Contributes to Hypoglycemia in Hyperinsulinemia Hyperammonemia by Inhibiting Glucagon Release
por: Kibbey, Richard G., et al.
Publicado: (2014)

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
por: Ja’arah, Daria, et al.
Publicado: (2021)

Cost of Severe Hypoglycemia and Budget Impact with Nasal Glucagon in Patients with Diabetes in Spain
por: Osumili, Beatrice, et al.
Publicado: (2022)

Why Glucagon Matters for Hypoglycemia and Physical Activity in Individuals With Type 1 Diabetes
por: Colberg, Sheri R.
Publicado: (2022)

Inhibition of Dipeptidyl Peptidase-4 by Vildagliptin During Glucagon-Like Peptide 1 Infusion Increases Liver Glucose Uptake in the Conscious Dog
por: Edgerton, Dale S., et al.
Publicado: (2009)

Chronic Administration of the Glucagon-Like Peptide-1 Analog, Liraglutide, Delays the Onset of Diabetes and Lowers Triglycerides in UCD-T2DM Rats
por: Cummings, Bethany P., et al.
Publicado: (2010)

Puzzling About Partial Glucagon Responses to Hypoglycemia in Intrahepatic Islet Recipients: Missing Pieces
por: Robertson, R. Paul
Publicado: (2015)

Hypothalamic Irak4 is a genetically controlled regulator of hypoglycemia-induced glucagon secretion
por: Picard, Alexandre, et al.
Publicado: (2022)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_cla3iq7899aqmlm5ma1ess5n5p